Portfolio
Harmony Biosciences (NASDAQ: HRMY) develops new treatment options for patients with sleep-wake disorders and other neurological conditions. The company developed and commercialized the first nonscheduled treatment for narcolepsy.
Emalex Biosciences is developing new treatments for central nervous system disorders. It is in late-stage development of a new class of drug for patients with Tourette syndrome and other conditions that have limited treatment options.
Evozyne uses generative AI to design novel protein systems and develop treatments for diseases with high unmet medical needs.
Castle Creek Biosciences is a late-stage cell and gene therapy company developing treatments for skin and connective tissue diseases. Castle Creek’s pipeline uses cutting-edge technologies that create optimal therapies for a broad range of genetic diseases.
CiRC Biosciences is pursuing life-changing regenerative medicines, with an initial goal of restoring vision lost to degenerative retinal diseases.
Qlarity Imaging is a privately held, AI-focused company. Qlarity assists radiologists in diagnosing breast abnormalities with its AI-driven technology.
